Page last updated: 2024-12-05

doxylamine succinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Doxylamine succinate is an antihistamine that is commonly used to treat allergies and the common cold. It is a white crystalline powder that is soluble in water. Doxylamine succinate works by blocking the effects of histamine, a chemical that is released by the body in response to an allergen. This blockage helps to reduce symptoms such as sneezing, runny nose, and itchy eyes. Doxylamine succinate is also used to prevent motion sickness. It is available over-the-counter (OTC) and by prescription. Doxylamine succinate is a combination of two drugs: doxylamine and succinic acid. Doxylamine is an antihistamine, and succinic acid is a weak acid that helps to stabilize the drug. Doxylamine succinate is synthesized by reacting doxylamine with succinic acid. The reaction is typically carried out in a solvent such as water or ethanol. The resulting product is then purified by recrystallization. Doxylamine succinate is a safe and effective drug for treating allergies and the common cold. However, it can cause side effects such as drowsiness, dry mouth, and constipation. It is important to talk to your doctor before taking doxylamine succinate, especially if you are pregnant, breastfeeding, or have any health conditions. Doxylamine succinate is studied for its potential to treat a variety of conditions, including insomnia, anxiety, and depression. It is also being studied for its potential to prevent motion sickness. Doxylamine succinate is a relatively inexpensive drug. It is available in both generic and brand-name forms. '

Cross-References

ID SourceID
PubMed CID11224
CHEMBL ID1200392
CHEBI ID82461
SCHEMBL ID160443
MeSH IDM0108466

Synonyms (188)

Synonym
AC-4487
v9bi9b5yi2 ,
safetussin
equaline sleep aid
doxylamine succinate liquid
topcare sleep aid
unii-v9bi9b5yi2
doxylamine succinate [usp]
MLS001076141
HMS3393F14
n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine succinate
EU-0100348
doxylamine succinate salt
PRESTWICK_887
cas-562-10-7
doxylamine succinate (1:1)
decapryn succinate
doxylamine succinate
phenyl2-pyridylmethyl-(.beta.-n,n-dimethylamino)ethyl ether succinate
unisom
[[[(2-dimethylamino)ethoxy]phenyl]methyl]-2-picoline succinate
a-h injection
evigoa d
butanedioic acid,n-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine (1:1)
decapryn
(dimethylamino)ethoxy-methyl-benzyl-pyridine succinate
decapryn succinate (1:1)
nsc-74772
562-10-7
wln: t6nj bx1&r&o2n1&1 &ov2vo
2-[[.alpha.-(2-dimethylamino)ethoxy]-.alpha.-methylbenzyl]pyridine succinate
pyridine, succinate (1:1)
2-dimethylaminoethoxyphenylmethyl-2-picoline succinate (1:1)
nsc74772
dimethylaminoethoxy-methyl-benzyl-pyridine succinate
mereprine
phenyl2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether succinate
doxy-sleep-aid
ccris 4811
einecs 209-228-7
2-dimethylaminoethoxyphenylmethyl-2-picoline succinate
alsadorm
ethanamine, n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-, butanedioate (1:1)
nsc 74772
gittalun
alpha-(2-dimethylaminoethoxy)-alpha-methyl-alpha-phenyl-2-picoline acid succinate
2-(alpha(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine succinate (1:1)
ai3-23993
sedaplus
doxylamine hydrogen succinate
hoggar n
2-(alpha-(2-dimethylaminoethoxy)-alpha-methylbenzyl)pyridine succinate
pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)-, succinate (1:1)
MLS000758288
decapryn (tn)
doxylamine succinate (usp)
D02327
NCGC00093785-03
NCGC00093785-02
NCGC00089789-03
smr000058436
MLS000028417 ,
SPECTRUM1500267
NCGC00093785-01
MLS002222274
NCGC00016140-02
HMS2051F14
D 3775
HMS2091B09
donormil
alsodorm
chebi:82461 ,
CHEMBL1200392
donormyl
meraprina
dormidina
HMS502K03
HMS1920K04
HMS1568E15
HMS2095E15
HMS3261E17
C19414
NCGC00256517-01
dtxsid7020552 ,
dtxcid10552
tox21_302861
NCGC00259627-01
tox21_113515
tox21_202078
pharmakon1600-01500267
nsc-756752
MLS001424137
nsc756752
HMS2231G05
S4240
CCG-38929
CCG-101033
NCGC00016140-04
NCGC00017028-02
NCGC00016140-03
FT-0625595
LP00348
HMS3370K04
AKOS025310916
doxylamine hydrogen succinate [ep monograph]
doxylamine succinate [mi]
doxylamine succinate [green book]
2-[alpha[2-(dimethylamino)ethoxy]-alpha-methylbenzyl]pyridine succinate (1:1)
decamium
doxylamine succinate [orange book]
doxylamine succinate component of bonjesta
bonjesta component doxylamine succinate
doxylamine succinate [iarc]
doxylamine succinate [mart.]
doxylamine succinate component of diclegis
bendectin component doxylamine succinate
diclectin component doxylamine succinate
doxylamine succinate [usp monograph]
n,n-dimethyl-2-((1rs)-1-phenyl-1-(pyridin-2-yl)ethoxy(ethanamine hydrogen butanedioate
doxylamine succinate component of bendectin
doxylamine succinate [usp-rs]
diclegis component doxylamine succinate
doxylamine succinate [who-dd]
doxylamine succinate [vandf]
doxylamine hydrogen succinate [ep impurity]
doxylamine (succinate)
CS-3232
HY-A0069
NC00283
SCHEMBL160443
tox21_113515_1
NCGC00021147-11
tox21_500348
NCGC00261033-01
F2173-1155
n,n-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethanamine succinate
OPERA_ID_566
mfcd00056168
butanedioic acid;n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
D-9200
doxylamine succinate, united states pharmacopeia (usp) reference standard
HMS3652H19
doxylamine for system suitability, european pharmacopoeia (ep) reference standard
doxylamine hydrogen succinate, european pharmacopoeia (ep) reference standard
doxylamine succinate, pharmaceutical secondary standard; certified reference material
doxylamine hydrogen succinate 1.0 mg/ml in methanol (as free base)
SR-01000003036-6
sr-01000003036
SR-01000003036-2
SR-01000003036-9
HMS3712E15
SW197008-4
butanedioic acid,n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
BCP24067
AS-13661
HMS3885D13
FT-0667789
D81886
butanedioic acid; dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine
EN300-123050
doxylamine for system suitability
n,n-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethanaminesuccinate
D5583
basic care sleep aid
doxylamine hydrogen succinate (ep impurity)
butanedioic acid, compound with n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine(1:1)
doxylamine succinate (usp monograph)
sambrosa
sambrosanight
nocto sleep aid
sleep aid25mg
unisom sleeptabs
wal som
dimethylaminoethoxymethylbenzylpyridine succinate
wal somnighttime sleep aid
a-h-tablets 100 mg, a-h-tablets 25 mg
doxylamine hydrogen succinate (ep monograph)
doxylamine succinate (iarc)
vicks zzzquilultra
phenyl 2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether succinate
n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy) ethanamine, butanedioate(1:1)
good sense sleep aid ultra
harris teeter sleep aid
doxylamine succinate (usp-rs)
doxylamine succinate (mart.)
sleep aid ultra
doxylamine.succinate, 1mg/ml in methanol
doxylamine.succinate

Research Excerpts

Overview

Doxylamine succinate is a commonly used antihistamine for respiratory allergies including allergic rhinitis as well as for the management of insomnia.

ExcerptReferenceRelevance
"Doxylamine succinate is a commonly used antihistamine for respiratory allergies including allergic rhinitis as well as for the management of insomnia."( Doxylamine succinate overdose: Slurred speech and visual hallucination.
Derinöz-Güleryüz, O, 2018
)
2.64

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic profile of Diclectin well explains its documented delayed efficacy."( Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
Koren, G; Nulman, I, 2009
)
0.59
" The data available on the pharmacokinetic profile of doxylamine in humans are limited, notwithstanding that this drug has been marketed in European countries for more than 50 years."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.38
"The objective of this study was to evaluate the pharmacokinetic parameters of doxylamine following a single oral dose of doxylamine hydrogen succinate 25 mg in healthy human subjects under fed and fasting conditions."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.38
" Pharmacokinetic parameters were calculated using noncompartmental analysis."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.38
" No statistically significant between-treatment differences were observed for any of the pharmacokinetic parameters under study."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.38
" Pharmacokinetic parameters were calculated using non-compartmental analysis."( Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteers.
Cabot, A; Cebrecos, J; Encabo, M; Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Videla, S; Wagner, F; Xu, Z, 2013
)
0.39
"5 mg: mean Cmax 61."( Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteers.
Cabot, A; Cebrecos, J; Encabo, M; Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Videla, S; Wagner, F; Xu, Z, 2013
)
0.39
" Pharmacokinetic parameters were estimated using non-compartmental methods and relationships with age were assessed using linear regression."( Doxylamine pharmacokinetics following single dose oral administration in children ages 2-17 years.
Balan, G; Gibb, R; Hull, D; Li, L; Seeck, M; Thompson, GA, 2013
)
0.39

Bioavailability

Doxylamine succinate 25 mg tablets exhibited similar oral bioavailability of doxylamine in the fasting state (mean maximum plasma drug concentration [C(max)] 118. Intranasal bioavailability was greater than that of oral doxylame succinate (70.3%)

ExcerptReferenceRelevance
" Intranasal bioavailability was greater than that of oral doxylamine succinate (70."( Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats.
du Plessis, J; du Preez, JL; Goosen, C; Müller, DG; Pelser, A, 2002
)
0.81
"Diclectin exhibited similar oral bioavailability to those of the oral solutions."( Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
Koren, G; Nulman, I, 2009
)
0.59
" Doxylamine succinate 25 mg tablets exhibited similar oral bioavailability of doxylamine in the fasting state (mean maximum plasma drug concentration [C(max)] 118."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
1.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Doxylamine succinate was used to determine distribution and excretion of the activity as a function of dose and sex with time. Three glucuronide metabolites were collected in a single fraction using high-performance liquid chromatography.

ExcerptRelevanceReference
"Three glucuronide metabolites of doxylamine succinate were collected in a single fraction using high-performance liquid chromatography (HPLC) from the urine of dosed male Fischer 344 rats."( Desorption chemical ionization and fast atom bombardment mass spectrometric studies of the glucuronide metabolites of doxylamine.
Gosnell, AB; Holder, CL; Korfmacher, WA; Lay, JO; Miller, DW; Siitonen, P, 1986
)
0.55
"Experiments were conducted with male and female rats (12 per group) dosed by gavage with 2 or 20 mg (based on the free amine) doxylamine succinate containing about 10 microCi 14C-doxylamine succinate to determine distribution and excretion of the activity as a function of dose and sex with time."( Metabolism of doxylamine succinate in Fischer 344 rats. Part I: Distribution and excretion.
Cmarik, JL; Gosnell, AB; Holder, CL; Rowland, KL; Siitonen, PH; Thompson, HC,
)
0.7
" Analytical chemical procedures that ensure proper concentration, homogeneity, and stability of the drug in dosed feed, as well as the safety of personnel and the environment, were prerequisites for the toxicological tests."( Trace analysis of doxylamine succinate in animal feed, human, urine, and wastewater by GC using a rubidium-sensitized nitrogen detector.
Bowman, MC; Holder, CL; Thompson, HC, 1982
)
0.6
" Statistics for dose-response trend tests are calculated within body weight strata and pooled to obtain an overall dose-response trend test."( Dose-response trend tests for tumorigenesis, adjusted for body weight.
Gaylor, DW; Kodell, RL, 1999
)
0.3
" These methods could be applied to determine DOX, PYR, and FA in their combined dosage forms."( Simultaneous determination of a ternary mixture of doxylamine succinate, pyridoxine hydrochloride, and folic acid by the ratio spectra-zero-crossing, double divisor-ratio spectra derivative, and column high-performance liquid chromatographic methods.
Pathak, A; Rajput, SJ,
)
0.38
" Plasma samples were obtained before and for 72 hours after dosing and analyzed for doxylamine using HPLC MS/MS."( Doxylamine pharmacokinetics following single dose oral administration in children ages 2-17 years.
Balan, G; Gibb, R; Hull, D; Li, L; Seeck, M; Thompson, GA, 2013
)
0.39
" All developed methods can be successfully applied for simultaneous spectrophotometric determination of doxylamine and pyridoxine both in laboratory-prepared mixtures and commercial dosage forms."( Advanced spectrophotometric chemometric methods for resolving the binary mixture of doxylamine succinate and pyridoxine hydrochloride.
Al-Degs, Y; Alin, A; Gergov, G; Kassarova, M; Katsarov, P; Pilicheva, B; Simeonov, V, 2018
)
0.71
"The corresponding methods are suitable to determine PYR and DOX in pure form, pharmaceutical dosage form, and in the presence of DOX DEG product."( Chemometric Quality Assessment of Doxylamine Succinate With Its Degradation Product: Implementation of Two Predictive Models on UV-Spectrophotometric Data of Anti-Emetic Binary Mixture.
Abd El-Hadi, HR; Eissa, MS; Eltanany, BM; Zaazaa, HE, 2022
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Other1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency0.77620.002541.796015,848.9004AID1347398
GLI family zinc finger 3Homo sapiens (human)Potency48.55770.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency0.97080.000221.22318,912.5098AID1259243
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.11680.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency34.44620.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.25350.000229.305416,493.5996AID743069; AID743075; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency0.13450.143427.612159.8106AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.021919.739145.978464.9432AID1159509
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.07080.540617.639296.1227AID2364; AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency70.79460.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID743202
gemininHomo sapiens (human)Potency2.05960.004611.374133.4983AID624296
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.84890.00419.962528.1838AID2675
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency4.46680.009610.525035.4813AID1479145
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.99531.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (65)

Assay IDTitleYearJournalArticle
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (23.44)18.7374
1990's8 (12.50)18.2507
2000's10 (15.63)29.6817
2010's22 (34.38)24.3611
2020's9 (14.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.80 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index202.52 (26.88)
Search Engine Supply Index3.55 (0.95)

This Compound (67.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (11.27%)5.53%
Reviews5 (7.04%)6.00%
Case Studies5 (7.04%)4.05%
Observational0 (0.00%)0.25%
Other53 (74.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Single Site, Open-label, Randomized, Two Treatments, Two Periods, Two Sequences, Crossover Trial to Evaluate the Bioequivalence of Two Delayed-release Oral Formulations of a Fixed Combination of Doxylamine Succinate 10 mg/Pyridoxine Hydrochloride 10 mg (T [NCT03905564]Phase 10 participants (Actual)Interventional2019-06-30Withdrawn(stopped due to Sponsor decision)
A Single-dose, Open-label, Multi-center Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Ages 2 to < 18 Years [NCT00796315]Phase 141 participants (Actual)Interventional2008-12-31Completed
A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy [NCT00614445]Phase 3280 participants (Actual)Interventional2008-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00614445 (1) [back to overview]Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).
NCT00796315 (2) [back to overview]AUC of Doxylamine
NCT00796315 (2) [back to overview]Cmax of Doxylamine

Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).

The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe). (NCT00614445)
Timeframe: Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)

InterventionPUQE Score (Mean)
Diclectin®-4.8
Placebo-3.9

[back to top]

AUC of Doxylamine

Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity. (NCT00796315)
Timeframe: 72 Hours

Interventionng*h/mL (Geometric Mean)
Subjects Aged 2-5 Years461.9
Subjects Aged 6-11 Years810.1
Subjects Aged 12-17 Years827.0

[back to top]

Cmax of Doxylamine

Maximum concentration of Doxylamine from 0 to 72 hours post-dose (NCT00796315)
Timeframe: 72 Hours

Interventionng/mL (Geometric Mean)
Subjects Aged 2-5 Years50.1
Subjects Aged 6-11 Years65.8
Subjects Aged 12-17 Years63.2

[back to top]